Biogen (BIIB)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$205.70-1.32%
Close 2026-07-07 · 1-day change
Reading BIIB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BIIB free→NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading BIIB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BIIB free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 1% over the past year.
View GrowthManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 2% a day.
View RiskBiogen's growth depends on its recent acquisition and strong earnings performance. Revenue grew 2% year over year, and the last quarter beat expectations by 23.5%. It trades at 13× P/E, below the peer median of 21×. This suggests the price reflects less growth than expected. A specific risk is the potential for guidance cuts, with a 13% chance of missing next quarter. Peer multiples imply a price about 26% above where it trades; this read is provisional.
Trailing returns as of 2026-07-07. BIIB is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 36 analysts currently covering BIIB (as of Jul 2026).
Based on 9 Wall Street analysts offering 12-month price targets for BIIB in the last 4 months.
A consensus fair price across 13 valuation methods, at three horizons. Current price $205.70. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Merger with Apellis Pharmaceuticals
Acquisition aligns with growth investment strategy.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $205.70
The last 12 months of price, then the range of analyst 12-month targets from today’s $205.70.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Merger with Apellis Pharmaceuticals
Trimming pipeline may hinder merger value realization.
Threatens: Merger with Apellis Pharmaceuticals
Scaling back Apellis programs undermines merger integration efforts.
Advances: Investment for growth
Acquisition supports growth investment objective.
Advances: Merger with Apellis Pharmaceuticals
Acquisition aligns with growth and capital allocation objectives.